Large-Diameter Gore Viabahn Approved to Treat Iliac Arteries

 

July 21, 2009—W. L. Gore & Associates (Flagstaff, AZ) announced that it has received approval from the US Food and Drug Administration (FDA) to market the latest design for the Gore Viabahn endoprosthesis with heparin bioactive surface for device diameters of 9 to 13 mm for the treatment of peripheral arterial disease (PAD) in the iliac artery. The product enables streamlined deployment on the same 0.035-inch guidewire and tip-to-hub direction as the 5- to 8-mm sizes. Additional modifications to the large-diameter Viabahn include radial device expansion, a contoured proximal edge, and a lower profile that is now available for most sizes.

According to Gore, the Viabahn family of endoprosthesis devices features a durable, reinforced, biocompatible, expanded polytetrafluoroethylene liner attached to an external nitinol stent structure. In 2005, the FDA approved the original device configuration of 6- to 8-mm sizes for treating PAD in the superficial femoral artery.

In 2007, the company added a 5-mm size, reduced its profile, and added a heparin bioactive surface. In 2008, 9- to 13-mm sizes were approved for improving blood flow in patients with symptomatic PAD in iliac artery lesions. In June 2009, the FDA approved a manufacturing change to the device to remove excess material at the device margin, resulting in a contoured edge at the proximal end. The Viabahn's flexibility enables it to traverse tortuous areas and to conform to the complex anatomy of the artery, the company stated.

"The latest improvements to the Gore Viabahn, including a smaller delivery profile and 0.035-inch guidewire compatibility for the larger diameter endografts, will allow us to easily deliver the larger devices to more locations," commented Michael B. Silva Jr, MD. "Treating difficult vascular problems requires good skills and good equipment. The self-expanding, covered Viabahn offers elegant and versatile endovascular solutions to difficult vascular problems."
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.